The Spanish biotech firm, Araclon, has contracted Ixico to conduct analysis results from it Alzheimer’s vaccine candidate. The vaccine, named ABvac40, is being tested in patients using imaging software to understand the drug’s impact on brain activity. The software will be comprised of an imagining data management platform trial tracker and an imagine analysis technology to evaluate patient eligibility, assess target engagement, and quantify the drug’s effectiveness. Read here.
